Holly Tovey

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

Andrew Tutt, Holly Tovey, Maggie C.U. Cheang et al. · Nature Medicine · 2018 · 903 citations · Full text

Medicine, Oncology, Pharmacology +11

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer

Isaac García-Murillas, Neha Chopra, Iñaki Comino‐Méndez et al. · JAMA Oncology · 2019 · 428 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

Neha Chopra, Holly Tovey, Alex Pearson et al. · Nature Communications · 2020 · 262 citations · Full text

Medicine, Oncology, Pharmacology +16

Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or <i>BRCA1/2</i> breast cancer (CRUK/07/012)

Andrew Tutt, Lucy Kilburn, Cheryl Gilett et al. · Cancer Research · 2015 · 166 citations

Medicine, Oncology, Pharmacotherapy +17

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

Christina Guo, Adam Sharp, Bora Gürel et al. · Nature · 2023 · 120 citations · Full text

Medicine, Oncology, Pharmacology +17